Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer

NCT03820141 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Durvalumab
DRUG: Trastuzumab
DRUG: Pertuzumab

Sponsor

The Methodist Hospital Research Institute

Collaborators

AstraZeneca